Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary.

Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation.

Washington (DC): National Academies Press (US); 2009.

2.

Using controlled clinical trials to learn more about acute drug-induced liver injury.

Watkins PB, Seligman PJ, Pears JS, Avigan MI, Senior JR.

Hepatology. 2008 Nov;48(5):1680-9. doi: 10.1002/hep.22633.

PMID:
18853438
3.

Acute liver cell damage in patients with anorexia nervosa: a possible role of starvation-induced hepatocyte autophagy.

Rautou PE, Cazals-Hatem D, Moreau R, Francoz C, Feldmann G, Lebrec D, Ogier-Denis E, Bedossa P, Valla D, Durand F.

Gastroenterology. 2008 Sep;135(3):840-8, 848.e1-3. doi: 10.1053/j.gastro.2008.05.055. Epub 2008 May 28.

PMID:
18644371
4.

Cellular imaging predictions of clinical drug-induced liver injury.

Xu JJ, Henstock PV, Dunn MC, Smith AR, Chabot JR, de Graaf D.

Toxicol Sci. 2008 Sep;105(1):97-105. doi: 10.1093/toxsci/kfn109. Epub 2008 Jun 3.

PMID:
18524759
5.

Systematic reviews of animal experiments demonstrate poor contributions toward human healthcare.

Knight A.

Rev Recent Clin Trials. 2008 May;3(2):89-96. Review.

PMID:
18474018
6.

PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes.

Thulin P, Rafter I, Stockling K, Tomkiewicz C, Norjavaara E, Aggerbeck M, Hellmold H, Ehrenborg E, Andersson U, Cotgreave I, Glinghammar B.

Toxicol Appl Pharmacol. 2008 Aug 15;231(1):1-9. doi: 10.1016/j.taap.2008.03.007. Epub 2008 Mar 26.

PMID:
18455211
7.

Applications of toxicogenomics to nonclinical drug development: regulatory science considerations.

Sistare FD, Degeorge JJ.

Methods Mol Biol. 2008;460:239-61. doi: 10.1007/978-1-60327-048-9_12.

PMID:
18449491
8.

An overview of drug-induced acute kidney injury.

Pannu N, Nadim MK.

Crit Care Med. 2008 Apr;36(4 Suppl):S216-23. doi: 10.1097/CCM.0b013e318168e375. Review.

PMID:
18382197
9.

New biomarkers of acute kidney injury.

Parikh CR, Devarajan P.

Crit Care Med. 2008 Apr;36(4 Suppl):S159-65. doi: 10.1097/CCM.0b013e318168c652. Review.

PMID:
18382188
10.

In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone.

Dykens JA, Jamieson JD, Marroquin LD, Nadanaciva S, Xu JJ, Dunn MC, Smith AR, Will Y.

Toxicol Sci. 2008 Jun;103(2):335-45. doi: 10.1093/toxsci/kfn056. Epub 2008 Mar 15.

PMID:
18344530
11.

Biomarkers of nephrotoxic acute kidney injury.

Ferguson MA, Vaidya VS, Bonventre JV.

Toxicology. 2008 Mar 20;245(3):182-93. doi: 10.1016/j.tox.2007.12.024. Epub 2008 Jan 4. Review.

12.

Monitoring kidney safety in drug development: emerging technologies and their implications.

Dieterle F, Marrer E, Suzuki E, Grenet O, Cordier A, Vonderscher J.

Curr Opin Drug Discov Devel. 2008 Jan;11(1):60-71. Review.

PMID:
18175268
13.

Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.

Wilke RA, Lin DW, Roden DM, Watkins PB, Flockhart D, Zineh I, Giacomini KM, Krauss RM.

Nat Rev Drug Discov. 2007 Nov;6(11):904-16. Review. Erratum in: Nat Rev Drug Discov. 2008 Feb;7(2):185.

14.

Tolcapone: an efficacy and safety review (2007).

Olanow CW, Watkins PB.

Clin Neuropharmacol. 2007 Sep-Oct;30(5):287-94. Review.

PMID:
17909307
15.

Preclinical predictors of clinical safety: opportunities for improvement.

Sistare FD, DeGeorge JJ.

Clin Pharmacol Ther. 2007 Aug;82(2):210-4. Epub 2007 May 16. Review.

PMID:
17507920
16.

Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis.

Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, Carlsson S, Cederbrant KE, Gibson NJ, Armstrong M, Lagerström-Fermér ME, Dellsén A, Brown EM, Thornton M, Dukes C, Jenkins SC, Firth MA, Harrod GO, Pinel TH, Billing-Clason SM, Cardon LR, March RE.

Pharmacogenomics J. 2008 Jun;8(3):186-95. Epub 2007 May 15.

PMID:
17505501
17.

Hepatic glycogenosis: an underrecognized source of abnormal liver function tests?

Sayuk GS, Elwing JE, Lisker-Melman M.

Dig Dis Sci. 2007 Apr;52(4):936-8. Epub 2007 Mar 7. No abstract available.

PMID:
17342391
18.

Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes.

Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP.

Gastroenterology. 2007 Jan;132(1):272-81. Epub 2006 Nov 17.

PMID:
17241877
19.

Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs.

Wagner JA, Williams SA, Webster CJ.

Clin Pharmacol Ther. 2007 Jan;81(1):104-7.

PMID:
17186007
20.

A novel mechanism for drug-induced liver failure: inhibition of histone acetylation by hydralazine derivatives.

Murata K, Hamada M, Sugimoto K, Nakano T.

J Hepatol. 2007 Feb;46(2):322-9. Epub 2006 Nov 3.

PMID:
17156885

Supplemental Content

Support Center